Dennis Ding
Stock Analyst at Jefferies
(1.97)
# 3,112
Out of 5,124 analysts
15
Total ratings
40%
Success rate
7.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $18 → $20 | $21.61 | -7.45% | 2 | Sep 18, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Hold | $15 → $26 | $35.71 | -27.19% | 2 | Sep 3, 2025 | |
| INDV Indivior | Assumes: Buy | $20 | $36.19 | -44.74% | 1 | Jul 22, 2025 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $45.95 | +19.70% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $2.00 | +300.00% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $30.58 | +14.45% | 1 | Sep 20, 2024 | |
| FOLD Amicus Therapeutics | Initiates: Buy | $18 | $14.28 | +26.05% | 1 | Sep 6, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $4.79 | +46.14% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $4.55 | +31.87% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $500 → $25 | $3.46 | +622.54% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $35 → $22 | $35.78 | -38.51% | 1 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $34.02 | -29.45% | 1 | Dec 19, 2022 |
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $18 → $20
Current: $21.61
Upside: -7.45%
Mineralys Therapeutics
Sep 3, 2025
Maintains: Hold
Price Target: $15 → $26
Current: $35.71
Upside: -27.19%
Indivior
Jul 22, 2025
Assumes: Buy
Price Target: $20
Current: $36.19
Upside: -44.74%
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $45.95
Upside: +19.70%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $2.00
Upside: +300.00%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $30.58
Upside: +14.45%
Amicus Therapeutics
Sep 6, 2024
Initiates: Buy
Price Target: $18
Current: $14.28
Upside: +26.05%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $4.79
Upside: +46.14%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $4.55
Upside: +31.87%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $500 → $25
Current: $3.46
Upside: +622.54%
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $35.78
Upside: -38.51%
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $34.02
Upside: -29.45%